The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerates the discovery of …

The persistent COVID-19 pandemic since 2020 has brought an enormous public health
burden to the global society and is accompanied by various evolution of the virus genome …

Background Recent evidence indicates a potential therapeutic role of fluvoxamine for
COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we …

Background The efficacy of ivermectin in preventing hospitalization or extended observation
in an emergency setting among outpatients with acutely symptomatic coronavirus disease …

Abstract Scope In January 2021, the ESCMID Executive Committee decided to launch a new
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …

Intestinal bacteria may influence lung homeostasis via the gut-lung axis. We conducted a
single-center, quadruple-blinded, randomized trial in adult symptomatic Coronavirus …

Objective To evaluate whether favipiravir reduces the time to viral clearance as documented
by negative RT-PCR results for severe acute respiratory syndrome coronavirus 2 in mild …

Platform trials are a type of randomized clinical trial that allow simultaneous comparison of
multiple intervention groups against a single control group that serves as a common control …

Motivation Platform designs-master protocols that allow for new treatment arms to be added
over time-have gained considerable attention in recent years. Between 2001 and 2019, 16 …

Summary Background Previous Randomised controlled trials (RCT) evaluating chloroquine
and hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant …